Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"

被引:9
作者
De Leonardis, F. [1 ]
Alivernini, S. [2 ]
Bonacci, E. [3 ]
Buono, A. M. [4 ]
Bombardieri, S. [5 ]
Ferraccioli, G. F. [2 ]
Montecucco, C. [3 ]
Sinigaglia, L. [6 ]
Trotta, F. [1 ]
Valentini, G. [4 ]
机构
[1] Univ Ferrara, Reumatol, Ferrara, FE, Italy
[2] Univ Cattolica Sacro Cuore Roma, Scuola Specializzaz Reumatol, Rome, Italy
[3] Univ Pavia, Reumatol, Pavia, Italy
[4] Seconda Univ Napoli, Reumatol, Naples, Italy
[5] Univ Pisa, Reumatol, Pisa, Italy
[6] Osped G Pini, UO Reumatol DH, Milan, Italy
关键词
Methotrexate; rheumatic diseases; rheumatoid arthritis; recommendations; guide-lines; evidence-based medicine; Delphi method;
D O I
10.4081/reumatismo.2010.34
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To develop a set of national evidence-based recommendations for the use of Methotrexate (MTX) in daily clinical practice. Methods: A panel of 37 Italian Rheumatologists reviewed 10 international recommendations formulated during the "3E (Evidence, Expertise, Exchange) initiative" for the year 2007-8, following a systematic literature search in Medline, Embase, Cochrane Library, and 2005-7 American College of Rheumatology/European League Against Rheumatism meeting abstracts and the revision of selected papers and the appraisal of Oxford levels of evidence. Moreover, the same panel by the same methodology formulated further 5 recommendations on topics previously selected by Italian representatives to 3E initiative. The agreement about the set of proposed recommendations was stated by a consensus process and the potential impact on clinical practice was assessed. Results: International Recommendations were analysed and changed when appropriate. In addition, 5 national recommendations were developed by identifying 6371 references, selecting and evaluating the 29 ones satisfying Evidence Based Medicine principles. Conclusions: A set of 15 national recommendations for the use of MTX in daily clinical practice was developed. These recommendations are evidence-based and integrate the expertise of a large panel of Italian rheumatologists.
引用
收藏
页码:34 / 45
页数:12
相关论文
共 54 条
[1]  
Agarwal V, 2004, J Assoc Physicians India, V52, P538
[2]   SURVIVAL AND DRUG DISCONTINUATION ANALYSES IN A LARGE COHORT OF METHOTREXATE-TREATED RHEUMATOID-ARTHRITIS PATIENTS [J].
ALARCON, GS ;
TRACEY, IC ;
STRAND, GM ;
SINGH, K ;
MACALUSO, M .
ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (09) :708-712
[3]  
ALAWADHI A, 1993, J RHEUMATOL, V20, P1121
[4]   Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis [J].
Barrera, P ;
van der Maas, A ;
van Ede, AE ;
Kiemeney, BALM ;
Laan, RFJM ;
van de Putte, LBA ;
van Riel, PLCM .
RHEUMATOLOGY, 2002, 41 (04) :430-439
[5]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[6]   Infliximab in active early rheumatoid arthritis [J].
Breedveld, FC ;
Emery, P ;
Keystone, E ;
Patel, K ;
Furst, DE ;
Kalden, JR ;
St Clair, EW ;
Weisman, M ;
Smolen, J ;
Lipsky, PE ;
Maini, RN .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (02) :149-155
[7]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[8]  
Castaneda O, 2006, J RHEUMATOL, V33, P862
[9]   A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate [J].
Cohen, SB ;
Moreland, LW ;
Cush, JJ ;
Greenwald, MW ;
Block, S ;
Shergy, WJ ;
Hanrahan, PS ;
Khraishi, MM ;
Patel, A ;
Sun, G ;
Bear, MB .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1062-1068
[10]   Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].
Cohen, Stanley B. ;
Emery, Paul ;
Greenwald, Maria W. ;
Dougados, Maxime ;
Furie, Richard A. ;
Genovese, Mark C. ;
Keystone, Edward C. ;
Loveless, James E. ;
Burmester, Gerd-Ruediger ;
Cravets, Matthew W. ;
Hessey, Eva W. ;
Shaw, Timothy ;
Totoritis, Mark C. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806